InflaRx surges on plans to seek emergency use authorization for COVID therapy

Inflarx NV

26/07/2022 13:37

** U.S.-listed shares of InflaRx N.V.  IFRX.O  jump ~12% to
$1.55 before the bell 
    ** German biopharma co says plans to seek emergency use
authorization from U.S. health regulator for its COVID-19
therapy, vilobelimab, by Q3-end  urn:newsml:reuters.com:*:nGNX809Z9y 
    ** Says completed meeting with U.S. Food and Drug
Administration, discussed details for late-stage study of
vilobelimab in critically ill COVID-19 patients
    ** Adds IFRX also committed to additional discussions with
FDA about further development of vilobelimab
    ** As of last close, IFRX down ~71% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))